According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Medications sold under brand names like Ozempic, Wegovy, and Saxenda have become famous for their weight-loss benefits, but ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Insulin changed the way we treat and manage diabetes. Chemotherapy has precipitously reduced the mortality rate of certain ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.